Your browser doesn't support javascript.
loading
Synthesis and biological evaluation of C-4 substituted phenoxazine-bearing hydroxamic acids with potent class II histone deacetylase inhibitory activities.
Chu, Jung-Chun; Tseng, Hui-Ju; Lee, Sung-Bau; Hsu, Kai-Cheng; Hsin, Ling-Wei; Liang, Ru-Hao; Lin, Tony Eight; Gao, Nain-Chu; Chen, Liang-Chieh; Lu, Wan-Hsun; Wang, Andrew H-J; Huang, Wei-Jan.
Afiliação
  • Chu JC; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
  • Tseng HJ; School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
  • Lee SB; Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California, United States.
  • Hsu KC; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
  • Hsin LW; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
  • Liang RH; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
  • Lin TE; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
  • Gao NC; TMU Research Center for Drug Discovery, Taipei Medical University, Taipei, Taiwan.
  • Chen LC; School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Lu WH; School of Pharmacy, Taipei Medical University, Taipei, Taiwan.
  • Wang AH; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
  • Huang WJ; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
J Enzyme Inhib Med Chem ; 38(1): 2212326, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37190931
ABSTRACT
Class II histone deacetylases (HDACs) are considered as potential targets to treat Alzheimer's disease (AD). Previously, C-3 substituted phenothiazine-containing compounds with class II HDAC-inhibiting activities was found to promote neurite outgrowth. This study replaced phenothiazine moiety with phenoxazine that contains many C-3 and C-4 substituents. Some resulting compounds bearing the C-4 substituent on a phenoxazine ring displayed potent class II HDAC inhibitory activities. Structure-activity relationship (SAR) of these compounds that inhibited HDAC isoenzymes was disclosed. Molecular modelling analysis demonstrates that the potent activities of C-4 substituted compounds probably arise from π-π stacked interactions between these compounds and class IIa HDAC enzymes. One of these, compound 7d exhibited the most potent class II HDAC inhibition (IC50= 3-870 nM). Notably, it protected neuron cells from H2O2-induced neuron damage at sub-µM concentrations, but with no significant cytotoxicity. These findings show that compound 7d is a lead compound for further development of anti-neurodegenerative agents.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácidos Hidroxâmicos / Antineoplásicos Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácidos Hidroxâmicos / Antineoplásicos Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article